English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18034/20233 (89%)
造訪人次 : 23771573      線上人數 : 805
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34514


    標題: Enhancement of cytotoxicity and induction of apoptosis by cationic nano-liposome formulation of n-butylidenephthalide in breast cancer cells
    作者: Huang, Xiao-Fan
    Chang, Kai-Fu
    Lin, Yu-Ling
    Liao, Kuang-Wen
    Hsiao, Chih-Yen
    Sheu, Gwo-Tarng
    Tsai, Nu-Man
    貢獻者: Chung Shan Med Univ, Inst Med
    Chung Shan Med Univ, Dept Med Lab & Biotechnol
    Acad Sinica, Agr Biotechnol Res Ctr
    Natl Chiao Tung Univ, Dept Biol Sci & Technol
    Natl Chiao Tung Univ, Inst Mol Med & Bioengn
    Ditmanson Med Fdn Chia Yi Christian Hosp, Div Nephrol, Dept Internal Med
    Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
    Chung Shan Med Univ Hosp, Clin Lab
    關鍵字: Polycationic liposome containing PEI and polyethylene glycol complex (LPPC)
    n-Butylidenephthalide (BP)
    Cell apoptosis
    Cell cycle
    Synergistic effect
    日期: 2021
    上傳時間: 2023-11-11 12:00:21 (UTC+8)
    出版者: IVYSPRING INT PUBL
    摘要: Breast cancer is the second most common malignancy in women. Current clinical therapy for breast cancer has many disadvantages, including metastasis, recurrence, and poor quality of life. Furthermore, it is necessary to find a new therapeutic drug for breast cancer patients to meet clinical demand. n-Butylidenephthalide (BP) is a natural and hydrophobic compound that can inhibit several tumors. However, BP is unstable in aqueous or protein-rich environments, which reduces the activity of BP. Therefore, we used an LPPC (Lipo-PEG-PEI complex) that can encapsulate both hydrophobic and hydrophilic compounds to improve the limitation of BP. The purpose of this study is to investigate the anti-tumor mechanisms of BP and BP/LPPC and further test the efficacy of BP encapsulated by LPPC on SK-BR-3 cells. BP inhibited breast cancer cell growth, and LPPC encapsulation (BP/LPPC complex) enhanced the cytotoxicity on breast cancer by stabilizing the BP activity and offering endocytic pathways. Additionally, BP and LPPC-encapsulated BP induced cell cycle arrest at the G0/G1 phase and might trigger both extrinsic as well as intrinsic cell apoptosis pathway, resulting in cell death. Moreover, the BP/LPPC complex had a synergistic effect with doxorubicin of enhancing the inhibitory effect on breast cancer cells. Consequently, LPPC-encapsulated BP could improve the anti-cancer effects on breast cancer in vitro. In conclusion, BP exhibited an anti-cancer effect on breast cancer cells, and LPPC encapsulation efficiently improved the cytotoxicity of BP via an acceleration of entrapment efficiency to induce cell cycle block and apoptosis. Furthermore, BP/LPPC exhibited a synergistic effect in combination with doxorubicin.
    關聯: INT J MED SCI, v.18, n.13, pp.2930-2942
    顯示於類別:[醫務管理系(所)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ijms.51439.pdf2458KbAdobe PDF27檢視/開啟
    index.html0KbHTML59檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋